ARCHIVES

UPCI Clarifies Agreement Between Eli Lilly And PCRN.

This article is from The Cancer Letter archive.

Vol. 27 No. 30 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

November 28, 2014

Freshman Congressman Launches Drive for “Adequate” Cancer Research Funding

August 5, 1983

HHS, MB, OSTP Urge President To Veto Biomedical Research Authorization; Senate Pushes FTE Levels

November 1, 1985

Arsenic Compound Improves Survival Of Adults With APL

February 23, 2007

Last Issue Until Aug. 20

July 30, 1982

NCI Proposes Inviting Academic Labs To Submit New Therapies For Development

January 23, 1998